COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma.

ABSTRACT: This summary presents 7-year results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) (COMBO group), against encorafenib alone (ENCO group), or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called advanced or metastatic BRAF V600-mutant melanoma.

SUBMITTER: Schadendorf D 

PROVIDER: S-EPMC12416198 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature